pp-224 Tablets
Dossier type
US CTD
Dossier status
Under development
Country of origin
United States
GMP approvals
FDA
Comments
Indication: Lewy Body Dementia Psychosis (LBDP)
Clinical stage: Phase 2
Modality: Small molecule muscarinic receptor antagonist / Mechanism & Target: Muscarinic-4 receptor antagonist
Route & form: Oral
Differentiation: Novel approach to neuropsychiatric symptoms in LBD
Manufacturer #39433
Clinical-stage biopharmaceutical company specializing in central nervous system disorders. Develops novel small molecules targeting psychiatric, neurological, and rare CNS conditions. Pursues multiple Phase 2 and Phase 3 programs through global development initiatives.
None